Premium
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Author(s) -
Tagawa Scott T.,
Beltran Himisha,
Vallabhajosula Shankar,
Goldsmith Stanley J.,
Osborne Joseph,
Matulich Dan,
Petrillo Kristen,
Parmar Sarojben,
Nanus David M.,
Bander Neil H.
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24795
Subject(s) - radioimmunotherapy , medicine , prostate cancer , glutamate carboxypeptidase ii , monoclonal antibody , toxicity , antigen , prostate , oncology , cancer , cancer research , antibody , immunology
Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate‐specific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized IgG monoclonal antibody developed to target the extracellular domain of PSMA. Preclinical and early phase clinical studies using radiolabeled J591 have demonstrated efficacy in targeting tumor cells and decreasing levels of prostate‐specific antigen. Radiolabeled J591 is well‐tolerated, nonimmunogenic, and can be administered in multiple doses. The dose‐limiting toxicity is reversible myelosuppression with little nonhematologic toxicity. Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti‐PSMA radioimmunotherapy. Cancer 2010;116(4 suppl):1075–83. © 2010 American Cancer Society.